-Reuters
SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $42
SVB Leerink analyst Andrew Berens maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform and lowers the price target from $67 to $42.